Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02075008 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
NCT02075008 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 270 participants.
The verdict
NCT02075008, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
Study Summary
This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.
Interventions
- DRUG QGE031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2014-03-27 |
| Est. Completion | 2016-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02075008
The ClinicalTrials.gov registry entry for NCT02075008 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QGE031 is the first listed.
NCT02075008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02075008 about?
NCT02075008 is a clinical study titled "Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201". This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.
What is the current status of trial NCT02075008?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2014-03-27. Estimated completion is 2016-03-22.
What interventions are being tested in trial NCT02075008?
The interventions under investigation include: QGE031 (DRUG).
Who is sponsoring clinical trial NCT02075008?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.